AstraZeneca commits $2 billion to partner Summit Therapeutics on bispecific cancer antibody
AstraZeneca has announced a $2 billion investment to work with Summit Therapeutics. The deal will fund the testing of Summit’s bispecific antibody, ivonescimab, which targets both PD‑1 and VEGF pathways.
The collaboration will pair ivonescimab with AstraZeneca’s own antibody‑drug conjugates, aiming to create a new combination approach for cancer treatment. Both companies said the partnership is intended to speed up clinical development and bring novel immuno‑oncology options to patients.
Analysts view the sizable commitment as a vote of confidence in Summit’s platform and a strategic move for AstraZeneca to broaden its oncology pipeline.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: AstraZeneca invests $2 billion in Summit Therapeutics”
read at STAT ↗
comments(0)
5-min edit window · permanent after that